Eduardo Bruno Martins

InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA.

SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA.

Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA.